Cannabinoids and gastrointestinal motility: Animal and human studies

European Review for Medical and Pharmacological Sciences

Volumn 12, Issue SUPPL. 1, 2008, Pages 81-93

  Aviello, G ^a   Romano, B ^a   Izzo, Angelo A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anandamide; Cannabinoid receptors; Fatty acid amide hydrolase; Gastric emptying; Inflammatory bowel disease; Intestinal motility; Irritable bowel syndrome; Myenteric plexus

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL; CANNABIS; DRONABINOL; ENDOCANNABINOID; RIMONABANT;

ABDOMINAL PAIN; ARTICLE; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INTESTINAL DYSMOTILITY; INTESTINE CONTRACTION; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; LOWER ESOPHAGUS SPHINCTER; MYENTERIC PLEXUS; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PERISTALSIS; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SEDATION; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; STOMACH MOTILITY; VOMITING;

ANIMALS; CANNABINOIDS; CANNABIS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; RECEPTORS, CANNABINOID; SYNAPTIC TRANSMISSION;

EID: 53249097849     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. DI CARLO G, IZZO AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 2003; 12: 39-49.
2. COUTTS AA, IZZO AA. The gastrointestinal pharmacology of cannabinoids. An update. Curr Opin Pharmacol 2004; 4: 572-579.
3. DUNCAN M, DAVISON JS, SHARKEY KA. Endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005; 22: 667-683.
4. IZZO AA, CAMILLERI M. Emerging role of cannabinoids in gastrointestinal and liver diseases: Basic and clinical aspects. Gut 2008 Apr 8.
5. PACHER P, BATKAI S, KUNOS G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
6. GUAGNINI F, VALENTI M, MUKENGE S, MATIAS I, BIANCHETTI A, DI PALO S, FERLA G, DI MARZO V, CROCI T. Neural contractions in colonic strips from patients with diverticulosis: Role of endocannabinoids and substance P. Gut 2006; 55: 946-953.
7. D'ARGENIO G, VALENTI M, SCAGLIONE G, COSENZA V, SORRENTINI I, DI MARZO V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006; 20: 568-570.
8. STORR MA, SHARKEY KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 2007; 7: 575-582.
9. DI MARZO V, IZZO AA. Endocannabinoid overactivity and intestinal inflammation. Gut 2006; 55;1373-1376.
10. DI MARZO V, PETROSINO S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18: 129-140.
11. AVIELLO G, MATIAS I, CAPASSO R, PETROSINO S, BORRELLI F, ORLANDO P, ROMANO B, CAPASSO F, DI MARZO V, IZZO AA. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med 2008; 86: 413-422.
12. FU J, ASTARITA G, GAETANI S, KIM J, CRAVATT BF, MACKIE K, PIOMELLI D . Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 2007; 282: 1518-1528.
13. DI MARZO V, CAPASSO R, MATIAS I, AVIELLO G, PETROSINO S, BORRELLI F, ROMANO B, ORLANDO P, CAPASSO F, IZZO AA. The role of endocannabinoids in the regulation of gastric emptying: Alterations in mice fed a high-fat diet. Br J Pharmacol 2008; 153: 1272-1280.
14. CAPASSO R, IZZO AA. Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. J Neuroendocrinol 2008; 20(Suppl 1): 39-46.
15. MASSA F, MARSICANO G, HERMANN H, CANNICH A, MONORY K, CRAVATT BF, FERRI GL, SIBAEV A, STORR M, LUTZ B. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-1209.
16. IZZO AA, AVIELLO G, PETROSINO S, ORLANDO P, MARSINO G, LUTZ B, BORRELLI F, CAPASSO R, NIGAM S, CAPASSO F, DI MARZO V. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 2008; 86: 89-98.
17. IZZO AA, CAPASSO F, COSTAGUOLA A, BIS0GNO T, MARSICANO G, LIGRESTI A, MATIAS I, CAPASSO R, PINTO L, BORRELLI F, CECIO A, LUTZ B, MASCOLO N, DI MARZO V. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 2003; 125: 765-774.
18. DARMANI NA. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions. Methods Mol Med 2006; 123: 169-189.
19. CORUZZI G, ADAMI M, GUAITA E, MENOZZI A, BERTINI S, GIOVANNINI E, SOLDANI G. Effects of cannabinoid receptor agonists on rat gastric acid secretion: Discrepancy between in vitro and in vivo data. Dig Dis Sci 2006; 51: 310-317.
20. 1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn-Schmiedeberg's Arch Pharmacol 2001; 363: 241-244.
21. IZZO AA, CAPASSO F. Marijuana for cholera therapy. Trends Pharmacol Sci 2006; 27: 7-8.
22. SANSON M, BUENO L, FIORAMONTI J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006; 18: 949-956.
23. LIGRESTI A, BISOGNO T, MATIAS I, DE PETROCELLIS L, CASCIO MG, COSENZA V, D'ARGENIO G, SCAGLIONE G, BIFULCO M, SORRENTINI I, DI MARZO V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003; 125: 677-687.
24. PATSOS HA, HICKS DJ, DOBSON RR, GREENHOUGH A, WOODMAN N, LANE JD, WILLIAMS AC, PARASKEVA C. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: A possible role for cyclooxygenase 2. Gut 2005; 54: 1741-1750.
25. 2 receptor: A good friend in the gut. Neurogastroenterol Motil 2007; 19: 704-708.
26. 2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br J Pharmacol 2008; 153: 263-270.
27. GOYAL RK, HIRANO I. The enteric nervous system. New Engl J Med 1996; 334: 1106-1115.
28. COSTA M, BROOKES SJ, HENNIG GW. Anatomy and physiology of the enteric nervous system. Gut 2000; 47(Suppl 4): 15-19.
29. DE GIORGIO R, BARBARA G, FURNESS JB, TONINI M. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci 2007; 28: 473-481.
30. ANAVI-GOFFER S, COUTTS AA. Cellular distribution of vanilloid VR1 receptor immunoreactivity in the guinea-pig myenteric plexus. Eur J Pharmacol 2003; 458: 61-71.
31. 1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000; 302: 73-80.
32. 1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol 2006; 148: 191-199.
33. WRIGHT K, ROONEY N, FEENEY M, TATE J, ROBERTSON D, WELHAM M, WARD S . Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005; 129: 437-453.
34. MASCOLO N, IZZO AA, LIGRESTI A, COSTAGLIOLA A, PINTO L, CASCIO MG, MAFFIA P, CECIO A, CAPASSO F, DI MARZO V. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASE J 2002; 16: 1973-1975.
35. PINTO L, IZZO AA, CASCIO MG, BISOGNO T, HOSPODAR-SCOTT K, BROWN DR, MASCOLO N, DI MARZO V, CAPASSO F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 227-234.
36. SANGER GJ. Endocannabinoids and the gastrointestinal tract: What are the key questions? Br J Pharmacol 2007; 152: 663-670.
37. IZZO AA, MASCOLO N, DI CARLO G, CAPASSO F. Ascending neural pathways in the isolated guinea-pig ileum: Effect of muscarinic M1, M2 and M3 cholinergic antagonists. Neuroscience 1999; 91: 1575-1580.
38. 2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacol Res 2007; 56: 185-192.
39. STORR M, GAFFAL E, SAUR D, SCHUSDZIARRA V ALLESCHER HD. Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol 2002; 80: 67-76.
40. 1 receptors. Br J Pharmacol 1998; 124: 1363-1368.
41. 1 receptors in guinea-pig small intestine. Br J Pharmacol 1996; 118: 2199-2205.
42. MULÈ F, AMATO A, BALDASSANO S, SERIO R. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. Pharmacol Res 2007; 56: 132-139.
43. COUTTS AA PERTWEE RG, Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997; 121: 1557-1566.
44. LÓPEZ-REDONDO F, LEES G M PERTWEE R G. Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum. Br J Pharmacol 1997; 122: 330-334.
45. STORR M, SIBAEV A, MARSICANO G, LUTZ B, SCHUSDZIARRA V, TIMMERMANS JP, ALLESCHER HD. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 2004; 286: G110-G1177.
46. HEINEMANN A, SHAHBAZIAN A, HOLZER P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999; 38: 1289-1297.
47. YUECE B, SIBAEV A, BROEDL UC, MARSICANO G, GÖKE B, LUTZ B, ALLESCHER HD, STORR M. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterol Motil 2007; 19: 744-753.
48. 1 ligands in the isolated guinea-pig ileum. Br J Pharmacol 2000; 129: 984-990.
49. MANCINELLI R, FABRIZI A, DEL MONACO S, AZZENA G B, VARGIU R, COLOMBO G C GESSA G L. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci 2001; 69: 101-111.
50. 1 receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. Eur J Pharmacol 2008; in press.
51. 1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134: 563-570.
52. CAPASSO R, MATIAS I, LUTZ B, BORRELLI F, CAPASSO F, MARSICANO G, MASCOLO N, PETROSINO S, MONORY K, VALENTI M, DI MARZO V, IZZO AA. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005; 129: 941-951.
53. IZZO AA, MASCOLO N, CAPASSO R, GERMANO MP, DEPASQUALE R, CAPASSO F . Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 360: 221-223.
54. 1 receptors. Eur J Pharmacol 1999; 371: 187-196.
55. 1 receptors. Eur J Pharmacol 2002; 450: 77-83.
56. 9-tetrahydrocannabinol in laboratory rodents. Arch Int Pharmacodyn 1972; 196: 133-145.
57. CHESHER GB, DAHL CJ, EVERINGHAM M, JACKSON DM, MARCHANT WILLIAMS H, STARMER GA. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol 1973; 49: 588-594.
58. SHOOK JE BURKS TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmac Exp Ther 1989; 249: 444-449.
59. 1 and opioid receptors in gastrointestinal motility in mice. Br J Pharmacol 2006; 148: 1043-1050.
60. IZZO AA, CAPASSO R, PINTO L, DI CARLO G, MASCOLO N, CAPASSO F. Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 2001; 132: 1411-1416.
61. 1 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 359: 65-70.
62. IZZO AA, MASCOLO N, PINTO L, CAPASSO R, CAPASSO F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999; 384: 37-42.
63. IZZO AA, PINTO L, BORRELLI F, CAPASSO R, MASCOLO N, CAPASSO F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000; 129: 1627-1632.
64. 1 receptor antagonist, SR 141716 (Rimonabant). Eur J Pharmacol 2004; 494: 221-224.
65. 1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. J Mol Med 2006; 84: 513-520.
66. MATHISON R, HO W, PITTMAN QJ, DAVISON JS, SHARKEY KA. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004; 142: 247-254.
67. MOAYYEDI P, TALLEY NJ. Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-2100.
68. LEHMANN A, BLACKSHAW LA, BRANDEN L, CARLSSON A, JENSEN J, NYGREN E, SMID SD. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002; 123: 1129-1134.
69. PARTOSOEDARSO ER, ABRAHAMS TP, SCULLION RT, MOERSCHBAECHER JM, HORNBY PJ. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003; 550: 149-158.
70. 1 receptors in human ileum. Br J Pharmacol 1998; 125: 1393-1395.
71. MANARA L, CROCI T, GUAGNINI F, RINALDI-CARMONA M, MAFFRAND J P, LE FUR G, MUKENGE S FERLA G. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis 2002; 34: 262-269.
72. GUAGNINI F, COGLIATI P, MUKENGE S, FERLA G, CROCI T. Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol 2006; 148: 1165-1173.
73. KANG JY, MELVILLE D, MAXWELL JD. Epidemiology and management of diverticular disease of the colon. Drugs Aging 2004; 21: 211-228.
74. SMID SD, BJORKLUND CK, SVENSSON KM, HEIGIS S, REVESZ A. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. Eur J Pharmacol 2008; in press.
75. 9-tetrahydro-cannabinol delays the gastric emptying of solid food in humans: A double-blind, randomized study. Aliment Pharmacol Ther 1999; 13: 77-80.
76. 9-tetrahydrocannabinol and gastric emptying. Br J Clin Pharmacol 1983; 15: 749-751.
77. ESFANDYARI T, CAMILLERI M, FERBER I, BURTON D, BAXTER K, ZINSMEISTER AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: A randomized, placebo-controlled study. Neurogastroenterol Motil 2006; 18: 831-838.
78. ESFANDYARI T, CAMILLERI M, BUSCIGLIO I, BURTON D, BAXTER K, ZINSMEISTER AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: A randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007; 293: G137-G145.
79. ANDRESEN V, CAMILLERI M. Irritable bowel syndrome: Recent and novel therapeutic approaches. Drugs 2006; 66: 1073-1088.
80. CAMILLERI M, CARLSON P, MCKINZIE S, GRUDELL A, BUSCIGLIO I, BURTON D, BAXTER K, RYKS M, ZINSMEISTER AR. Genetic variation in endocannabinoid metabolism, gastrointestinal motility and sensation. Am J Physiol Gastrointest Liver Physiol 2008; in press.
81. BROWN AJ. Novel cannabinoid receptors. Br J Pharmacol 2007; 152: 567-575.
82. HOLZER P. TRPV1 and the gut: From a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 2004; 500: 231-241.
83. MCVEY DC, SCHMID PC, SCHMID HH, VIGNA SR. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther 2003; 304: 713-722.
84. 1 cannabinoid receptors. Br J Pharmacol 2001; 134: 161-167.
85. BEGG M, MOLLEMAN A PARSONS M. Modulation of the release of endogenous gamma-aminobutyric acid by cannabinoids in the guinea pig ileum. Eur J Pharmacol 2002; 434: 87-94.
86. BARTHÓ L, BENKÓ R, LÁZÁR Z, ILLÉNYI L, HORVÁTH OP. Nitric oxide is involved in the relaxant effect of capsaicin in the human sigmoid colon circular muscle. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 366: 496-500.
87. KOJIMA S, SUGIURA T, WAKU K, KAMIKAWA Y. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur J Pharmacol 2002; 444: 203-207.
88. VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, RÖSSNER S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
89. CAPASSO R, BORRELLI F, AVIELLO G, ROMANO B, SCALISI C, CAPASSO F, IZZO AA. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 2008 May 12.